Skip to content

Author

Dian-Sheng Zhong

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study

Acquired BRAF V600E is an uncommon resistance mechanism after tyrosine kinase inhibitor (TKI) therapy in oncogene-driven non-small cell lung cancer (NSCLC), and the clinical value of dabrafenib/trametinib-based combination therapy remains unclear. This preliminary single-center retrospective study aimed to describe...

Dan Xu, Fang Hao, Xia Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.